Cost-effectiveness of a proportionate universal offer of free exercise: Leeds Let's Get Active

CURRENT STATUS: POSTED

Paolo Candio
Health Economics Research Centre

✉ paolo.candio@ndph.ox.ac.uk Corresponding Author
ORCiD: https://orcid.org/0000-0003-1521-088X

David Meads
University of Leeds School of Healthcare

Andrew J. Hill
University of Leeds School of Healthcare

Laura Bojke
University of York

Abstract

Objectives To assess the cost-effectiveness of a proportionate universal programme to reduce physical inactivity (Leeds Let's Get Active) in adults.

Methods A continuous-time Markov chain model was developed to assess the cost implications and QALY gains associated with increases in physical activity levels across the adult population. An ordered logistic model was specified to estimate the effectiveness of the Leeds Let's Get Active programme and derive transition probabilities between physical activity categories. A parametric survival analysis approach was applied to estimate the decay of intervention effect over time. Baseline model data were obtained from previous economic models, population-based surveys and other published literature. A cost-utility analysis was conducted from a health care sector perspective over the programme duration (39 months). Scenario and probabilistic sensitivity analyses were performed to test the robustness of cost-effectiveness results.

Results 51,874 adult residents registered to the programme and provided baseline data, 19.5% of which were living in deprived areas. Under base case assumptions, Leeds Let's Get Active was found to be likely to be cost-effective. However, variations in key structural assumptions showed sensitivity of the results.

Conclusions Evidence from this study suggests that a universal offer of access to free off-peak leisure centre-based exercise that targets hard to reach groups can provide good value for money. Further data collection is needed to reduce the uncertainty surrounding the decision.

Introduction

Lack of regular physical activity (PA) is a major contributor to chronic disease and mortality in developed countries[1]. Physical inactivity increases the risk of many chronic conditions, determining 9% of all premature mortality worldwide[2], and impacting substantially on national health care budgets[3]. In the UK, physical inactivity accounts for £1 billion a year to the national health system, with estimates rising to around £7.4 billion when taking a societal perspective[4].

Cost-effectiveness analysis is used to inform decisions regarding which interventions should be commissioned[5]. Evidence on the cost-effectiveness of PA interventions has accumulated over the last

two decades, though mostly on individual-level approaches[6]. While population-level interventions have been found to be cost-effective in the majority of cases, the number of these studies is currently limited, especially those assessing interventions aimed to reduce the number of physically inactive adults [7].

Leeds Let's Get Active (LLGA) was a city-wide programme developed by the Local Authority and funded in collaboration with Sport England and Public Health England, which was aimed to reduce physical inactivity levels in the local adult population. The LLGA offer consisted of provision of universal access to free off-peak City Council leisure centre-based exercise sessions to all city residents. In order to encourage residents from low socio-economic backgrounds to take up the offer, LLGA sessions were provided in 17 centres located in the most deprived areas of the city. Exercise sessions included the use of free weight areas, swimming pool access and fitness classes. This form of LLGA ran for 39 months, from October 2013 to the end of December 2016. This paper reports the results of a cost-utility analysis to determine the cost-effectiveness of the LLGA programme.

Methods

Physical activity

At baseline and recruitment to the LLGA programme, participants were asked to self-report their current level of PA. This was based on a single-item question derived from the short-form IPAQ questionnaire[8], which asked how many active days (defined as days with at least 30 minutes of at least moderate PA[9]) they had over the past week. Access to the free sessions was electronically monitored by means of a card participants were required to swipe at the leisure centre gates. No restrictions were imposed in terms frequency of access to the free exercise sessions. Following registration, a convenience sample of participants were surveyed a second time, either in person at the leisure centre or on-line.

Measures of behaviour change

In the cost-effectiveness analysis, programme effectiveness is defined as the ability of LLGA to affect a change in PA category. Four PA categories were defined according to the current UK PA

recommendations for adults[10]: inactive = zero, insufficiently active = 1 or 2, moderately active = 3 or 4, active = 5 to 7 active days a week. Two measures of behaviour change were available. The first (hereinafter "survey measure") was based on the survey data only, as the change in self-reported PA category observed between baseline and post-registration. The second measure (hereinafter "card swipe measure") was calculated as the probability of participants to improve baseline PA category due to a weekly access to LLGA sessions. Card swipe data were also analysed to obtain LLGA attendance drop-off patterns (i.e. time period between first and last LLGA session attended or end of the programme), which were used as a proxy for decay of intervention effect over time.

Analysis approach

For base-case estimation of effectiveness, a complete case analysis approach was applied in line with a previous similar study[11]. An ordered logistic regression model was specified, with subsequent estimation of PA transition probabilities. Stata software version 14 was used for all regression analyses.

Intervention costs

Appendix I includes the financial audit reports provided by LLGA administrators which include the cost breakdown by project function/component. To align with the approach currently adopted to inform reimbursement decisions by the NHS[12], the budget expenditure was assumed to represent the opportunity cost of implementing the intervention, under a constrained budget at a current £20,000 - £30,000 willingness-to-pay (WTP) threshold range[13]. The unit programme cost was therefore calculated by dividing the allocated budget by the number of programme participants.

Decision-analytic model

Building on previous decision-analytic models[11 14 15], a continuous-time state-transition Markov model was developed to estimate incremental costs and QALYs associated with implementing a LLGA programme, relative to a no-intervention alternative, in the adult general population. A schematic of the model is shown in Fig. 1.

All participants start the model in the healthy state. This state is a nested Markov chain consisting of

4

four PA states. The model allows for transition between the four PA states over time. An integrated

parametric survival approach allows for time-dependent PA transition probabilities to be specified.

The model simulates progression from a healthy state, to death or any of the identified diseases from

which a member can only stay or die in the subsequent cycles, until the cohort reaches 100 years of

age.

Utility decrements were used to model utility losses due to a disease diagnosis. Seven chronic

diseases and conditions were included[16]. Specifically, Type II Diabetes, Coronary heart disease,

Stroke, Colorectal, Breast cancer, Depression and Frailty syndrome. In line with the available

evidence, the probability of developing a Frailty syndrome starts at age 65. Time-independent risks of

developing one of the diseases are conditional on index of multiple deprivation (IMD) status (deprived

or non-deprived) and PA level, which were assumed independent factors. In order to capture

variations in utility due to changes in PA category before a diagnosis of disease, utility values were

attached to each PA/IMD state. Once within a particular a disease state, a participant faced an

increased probability of dying from all-causes. Thus, the 12 states represented constitute the four PA

categories, the seven diseases and death.

Model parameters

Model parameters were sourced from previous economic models, published literature and national

statistics, giving priority to UK-based evidence. Utility values, unit costs for treatment and

management of the seven diseases, deprivation and PA gradients of morbidity and disease-related

risks of all-cause mortality (i.e. relative risks) were searched using Medline database. Because there

were insufficient published data describing all the differential risks, to estimate the relative risks for

the intermediate categories, a linear interpolation method was employed as necessary, assuming a

linear dose-response relationship. Table 1 reports the model baseline parameters and distributions.

Table 1

MODEL PARAMETERS AND DISTRIBUTIONS

Model parameters	Health state	Parameter	Source / Method	Distribution
Annual prob ACT	T2D	0.002 (0.002)	Joseph, et al. [24]	Beta
	CHD	0.008 (0.0005)	Frew, et al.[11]	Beta
	STR	0.011 (0.0031)	Sattelmair, et al.[25]	Beta
	CRC	0.003 (0.003)	Frew, et al.[11]	Beta

	BRC	0.011 (0.001)	Frew, et al.[11]	Beta
	DEP	0.011 (0.0106)	National Institute for Health and Care Excellence [26]	Beta
	FRA	0.023 (0.023)	Fried, et al. [27]	Beta
RR INA	T2D	1.700 (1.7)	Roux, et al. [15]	LogNormal
	CHD	1.500 (1.5)	Roux, et al. 15	LogNormal
	STR	1.300 (1.3)	Roux, et al. 15	LogNormal
	CRC	1.600 (1.6)	Roux, et al. 15	LogNormal
	BRC	1.300 (1.3)	Roux, et al. 15	LogNormal
	DEP	1.150 (1.15)	Meng and D'Arcy [28]	LogNormal
	FRA	1.429 (1.43)	McPhee, et al. [29]	LogNormal
RR INS	T2D	1.525 (1.52)	Linear interpolation	LogNormal
	CHD	1.375 (1.137)	Linear interpolation	LogNormal
	STR	1.225 (1.225)	Linear interpolation	LogNormal
	CRC	1.450 (1.45)	Linear interpolation	LogNormal
	BRC	1.225 (1.225)	Linear interpolation	LogNormal
	DEP	1.113 (1.11)	Linear interpolation	LogNormal
	FRA	1.321 (1.32)	Linear interpolation	LogNormal
RR MOD	T2D	1.292 (1.29)	Linear interpolation	LogNormal
	CHD	1.208 (1.208)	Linear interpolation	LogNormal
	STR	1.125 (1.125)	Linear interpolation	LogNormal
	CRC	1.250 (1.25)	Linear interpolation	LogNormal
	BRC	1.125 (1.125)	Linear interpolation	LogNormal
	DEP	1.063 (1.063)	Linear interpolation	LogNormal
	FRA	1.179 (1.179)	Linear interpolation	LogNormal
RR IMD	T2D	1.250 (0.041)	Sharma, et al. [30]	LogNormal
	CHD	1.294 (1.29)	Bajekal, et al. [31]	LogNormal
	STR	1.400 (1.4)	Bray, et al. [32]	LogNormal
	CRC	1.100 (1.1)	Cancer Research UK [33]	LogNormal
	BRC	0.860 (0.86)	Cancer Research UK [33]	LogNormal
	DEP	1.170 (0.296)	Walters, et al. [34]	LogNormal
	FRA	1.100 (0.11)	Curtis, et al. [35]	LogNormal
RR death	T2D	1.850 (0.332)	Nwaneri, et al. [36]	LogNormal
	CHD	1.900 (0.161)	Vlachopoulos, et al. [37]	LogNormal
	STR	1.900 (0.161)	Vlachopoulos, et al. [37]	LogNormal
	CRC	1.449 (1.45)	Cancer Australia [38]	LogNormal
	BRC	1.320 (0.041)	Christiansen, et al. [39]	LogNormal
	DEP	1.520 (0.036)	Cuijpers, et al. [40]	LogNormal
	FRA	2.700 (0.74)	Kulmala, et al. [41]	LogNormal
Utility decrements	T2D	0.062 (0.06)	Sullivan and Ghushchyan [42]	Gamma
	CHD	0.056 (0.06)	Gulliford, et al. [14]	Gamma
	STR	0.101 (0.101)	Gulliford, et al. [14]	Gamma
	CRC	0.038 (0.038)	Gulliford, et al. [14]	Gamma
	BRC	0.015 (0.015)	Sullivan, et al. [43]	Gamma
	DEP	0.130 (0.13)	Gulliford, et al. [14]	Gamma
	FRA	0.177 (0.18)	Lin, et al. [44]	Gamma
Utility values IMD NON-DEPRIVED	INA	0.935 (0.0221)	HSE 2014 data analysis	Beta
	INS	0.985 (0.0218)	HSE 2014 data analysis	Beta
	MOD	0.997 (0.0223)	HSE 2014 data analysis	Beta
	ACT	0.982 (0.0219)	HSE 2014 data analysis	Beta
Utility values IMD	INA	0.935 (0.0221)	HSE 2014 data	Beta

Utility values IMD DEPRIVED	INA	0.935 (0.0221)	HSE 2014 data analysis	Beta
	INS	0.979 (0.0228)	HSE 2014 data analysis	Beta
	MOD	0.981 (0.0239)	HSE 2014 data analysis	Beta
	ACT	0.986 (0.0225)	HSE 2014 data analysis	Beta
Treatment and management costs	T2D	£ 1,363	Frew, et al.[11]	Fixed
	CHD1	£ 3,489	Frew, et al.[11]	Fixed
	CHD2	£ 105	Frew, et al.[11]	Fixed
	STR1	£ 9,630	Frew, et al.[11]	Fixed
	STR2	£ 2,396	Frew, et al.[11]	Fixed
	CRC	£ 9,999	Frew, et al.[11]	Fixed
	BRC	£ 9,091	Frew, et al.[11]	Fixed
	DEP	£ 139	Thomas and Morris [45]	Fixed
	FRA	£ 3,351	McNamee, et al. [46]	Fixed

Notes: HSE = Health Survey for England; IMD = Index of Multiple Deprivation status; prob = probability; INA = inactive; INS = insufficiently active; MOD = moderately active; ACT = active; T2D = Type II Diabetes; CHD1 = Coronary Heart Disease, first year from event; CHD2 = Coronary Heart Disease, second and subsequent years; STR1 = Stroke, first year from event; STR2 = Stroke, second and subsequent years; CRC = Colorectal Cancer; BRC = Breast Cancer; DEP = Depression; FRA = Frailty syndrome, RR = Relative Risk

National life tables were used to inform time-dependent background mortality risks from all causes.

Utility data for the PA states were obtained from analysis of the Health Survey for England 2014 data.

Following the approach used in a relevant published study[17], multivariate regressions were performed to estimate utility values as a function of IMD status and PA level.

The baseline PA category / number of active days was assumed to represent participants' PA habit before exposure to LLGA offer, which was assumed to remain constant over time (i.e. parallel trend assumption). The baseline age and proportions of PA habits in each of the two IMD deprivation groups corresponded to that of programme participants.

Economic evaluation

The decision problem was evaluated from a health care sector perspective, aligning the methods with previous economic evaluations[11 14]. A cost-utility analysis was conducted considering a programme duration time horizon to reflect a time that funders would find useful. Discount rate was set at an annual 1.5% for costs and outcomes. To facilitate the interpretation of cost-effectiveness results, the incremental net monetary benefit was calculated by multiplying the difference in QALYs between the two intervention options by £20,000 (lower bound of the WTP for a QALY gain), minus the costs associated with no-intervention[18].

Sensitivity analysis

Scenario and probabilistic sensitivity analyses were performed to characterise the uncertainty surrounding the decision. First, an alternative lifetime time horizon was considered. Second, the measure of effectiveness was varied by using the card swipe data collected which implied that LLGA participants could only improve PA category by actively attending its free sessions. Third, a last-observation-carried-forward approach was applied to the survey measure. Therefore, zero change in PA level was assumed for participants for whom no follow-up outcome measurement was available. Finally, the assumption regarding the sustainability of the intervention over time was tested by assuming a no decay and a gradual return to baseline PA level (using the LLGA session drop-off pattern as a proxy).

A Monte Carlo simulation was used to propagate the uncertainty through the model and allow model parameters to vary simultaneously[18].

Results

51,874 adult residents registered to the LLGA programme and provided basic baseline data. Participants were aged 39 years old on average, and the majority were female (62.4%) and living in non-deprived areas of the city (80.5%). A total of 191,605 LLGA sessions were accessed by 20,967 participants over the 39 months of programme.

Table 2 below reports the frequency distribution of PA categories observed at baseline and post-registration by IMD status. For 547 participants, full survey outcome data were available for the base-case analysis. Of these, 50.5% increased their baseline PA category, 36.9% did not change it, while 12.4% reported a lower PA level. Of the 20,967 participants attending at least one LLGA session, 529 improved their baseline PA category through a weekly participation to the free sessions. Participants from IMD deprived areas started at an overall lower PA level at baseline than the non-deprived group. Post-registration distributions of PA categories were found to be comparable between the two subgroups, indicating an only marginal difference in terms of intervention effect.

8

Table 2

Baseline and post-registration frequency distribution of PA categories

PA measurement (n)	INA	INS	MOD	ACT
Baseline PA (n = 41,737) IMD non-deprived	28.1%	37.6%	21.7%	12.6%
Baseline PA (n = 10,137) IMD deprived	32.8%	34.9%	20.1%	12.2%
Post-registration survey (n = 461) IMD non-deprived	7.6%	32.7%	41.9%	17.8%
Post-registration survey (n = 86) IMD deprived	5.8%	30.2%	46.5%	17.4%
Post-registration card swipes IMD non-deprived (n = 17,460)*	24.3%	33.9%	23.8%	14.2%
Post-registration card swipes IMD deprived (n = 3,507)*	27.7%	35.9%	22.9%	13.4%
*a total of 529 improved baseline PA category within the first 6 months after registration.				
INA = inactive, INS = insufficiently active, MOD = moderately active, ACT = active. IMD = Index of Multiple Deprivation				

Cost-effectiveness

Population-level costs, QALYs and incremental (deterministic) results are presented for the LLGA

programme versus no scheme (see Table 3). Under base-case assumptions, LLGA shows to be the

optimal strategy with an ICER of £555, well below the lower bound of the current WTP in the UK

(£20,000) and providing an average positive INMB of £174 per participant. When varying the time

horizon to a lifetime, LLGA becomes the dominant strategy, with negative incremental costs and QALY

gains, and a per-participant INMB of £802. Comparable results are found when assuming no decay of

intervention effectiveness over time and a gradual return to baseline PA level, with INMBs at £896

and at £619, respectively. Conversely, if effectiveness parameters are based on the card swipe

measure or if zero change in PA category is assigned to participants not providing a follow-up survey

measurement (last observation carried forward), LLGA is shown not to be cost-effective.

Table 3

Total costs, QALYs and incremental cost-effectiveness results: base-case vs scenario analysis

		Total cost (£)	Total QALY	Incremental cost (£)	Incremental QALY	Incremental cost per QALY (£)	Incremental Net Monetary Benefit
Base-case analysis (39 months)	LLGA	£ 3,623.65	3.0084	£ 4.97	0.00896	£ 555	£ 174
	no LLGA	£ 3,618.68	2.9994				
Lifetime	LLGA	£ 158,385.94	25.9405	-£ 100.61	0.03506	Dominant	£ 802
	no LLGA	£ 158,486.55	25.9054				
Card swipe measure	LLGA	£ 3,647.86	2.9995	£ 29.18	0.00005	£ 567,088	-£ 28
	no LLGA	£ 3,618.68	2.9994				
Last observation carried forward	LLGA	£ 3,647.92	2.9995	£ 29.24	0.00002	£ 1,315,249	-£ 29
	no LLGA	£ 3,618.68	2.9994				
No decay of intervention effect	LLGA	£ 3,522.62	3.0394	-£ 96.06	0.03998	Dominant	£ 896
	no LLGA	£ 3,618.68	2.9994				
Gradual return to baseline PA level	LLGA	£ 3,557.39	3.0273	-£ 61.29	0.02789	Dominant	£ 619
	no LLGA	£ 3,618.68	2.9994				

Figure 2 shows one thousand model iterations of the cost and QALY joint density plotted on a cost-effectiveness plane, comparing LLGA intervention to a no-intervention scenario (set as the origin), under base-case assumptions. Looking at the distribution of cost and QALY pairs, the majority fall below the WTP lower bound, indicating that there is a high probability of LLGA being the optimal alternative. Figure 3 shows the probability of LLGA being cost-effective, across a range of WTP thresholds. The cost-effectiveness acceptability curve (CEAC) did not cut the y-axis at zero (i.e. 55%) indicating that part of the joint density involved cost-savings[19]. Reflecting what was displayed in Fig. 2, there is a high probability (95%) of LLGA being the optimal strategy was found when considering a £20,000 threshold.

Discussion

Main findings

Results from this cost-utility analysis indicate that LLGA is likely to be cost-effective under base-case assumptions. The net benefits of implementing LLGA increase as a longer time horizon is considered. Scenario analyses also show that identification of the optimal strategy is highly dependent on variations to the effectiveness measure and key structural elements regarding the sustainability of

the intervention effect over time and assumed mechanisms of survey non-response.

Comparison with other studies

This study can be placed within the currently limited economic evaluation literature on population-level promotion of PA. In particular, the economic evaluation conducted to assess the cost-effectiveness of the BeActive programme[11]. This represents the main comparison study. LLGA mirrored the BeActive intervention modality, except that LLGA was offered only in City Council leisure centres located in the most deprived areas of the city. This afforded an opportunity to test the cost-effectiveness of providing universal access to free off-peak leisure centre-based sessions in another similar setting. For BeActive, base-case cost-effectiveness estimates were not dissimilar from those reported here, with an estimated £400 incremental cost per QALY gained. This finding supports the hypothesis that this type of population-level intervention represents good value for money also in the short term, and even when the offer is proportionate to attract hard to reach groups. By contrast with this study, BeActive appeared to be cost-effective even under the most conservative assumptions, though no further details were reported. Another comparable study simulated the implementation of a primary care-based universal intervention and found a 64.7% probability of the intervention being cost-effectiveness at a WTP threshold of £30,000.[14] One possible explanation for this difference in results is that, in that study, utility gains were accumulated only as a function of reduction in disease incidence and no utility gains were assigned from transitions to higher PA levels. Nevertheless, although some of the economic evaluation methods used in the present analysis were aligned with those studies (e.g. perspective, short time horizon), differences in the structures and parameters of the economic models limited the ability to directly compare our findings.

Strengths and limitations

To the best of our knowledge, this represents the first cost-utility analysis of a proportionate universal programme to promote free off-peak leisure centre-based exercise in the general population. The programme is relatively easy to incorporate into currently operating public leisure centres (off-peak sessions), and therefore this intervention has the potential to be replicated in other comparable

settings (i.e. local City Councils in the UK). As a result, this makes the evidence generated by this analysis particularly important for decision-makers that may be interested in evaluating the impact of implementing this type of intervention in the future.

The study is however subject to a number of limitations. In particular were the lack of experimental design, a non-research led data collection and handling process and restrictions imposed in terms of further data collection on residents/participants. This meant making the validity of effectiveness results depend on the plausibility of a parallel trend assumption, representativeness of the sample of participants providing full outcome data, as well as on untested measures of PA behaviour change which in turn relied on self-report. Previous similar studies share these limitations that cannot be overcome retrospectively and are likely to characterise large-scale programmes. Furthermore, while a sub-group analysis was conducted to account for heterogeneous effects, one of the objective of public health decision-makers is to reduce existing health inequality, which, due to resource constraints, was not possible to ascertain within this study.

Application of the QALY as the consequence considered in the evaluation restricted the evaluative space accordingly, therefore excluding non-health effects potentially generated by the intervention (e.g. increased work-related productivity[20]). However, in line with previous models[11 15 21], the decision-analytic model used for economic evaluation of LLGA was designed to accumulate utility gains/losses as a result of changes in PA state.

A de novo decision-analytic model was developed building on previous models, by incorporating a continuous-time structure which allowed for testing the assumption related to the sustainability of behaviour change over time. Nonetheless, this analysis still relied upon other structural assumptions relating to a fully elastic dose-response relationship between changes in PA and health, compensatory or synergistic effects potentially occurred on the path to health improvement (e.g. changes in dietary habits), increased health expenditure from extended life expectancy, and adverse events (e.g. injuries) which were not formally taken into account. Nevertheless, unlike previous models, negative intervention effects were captured informally by allowing the four PA states to move freely between one another.

12

Further, these results, like those presented in previous similar studies, rely on a set of structural assumptions which have not been verified yet and have the potential to impact identification of the optimal intervention. In particular, although the decision-analytic model used for this economic evaluation allows for "natural" transitions between PA states to be captured, due to lack of relevant data, PA states were assumed to be stable over time in absence of the intervention. However, this may not always be necessarily the case, especially in the short term [22] and during sensitive life phases (e.g. retirement [23]). Furthermore, since the effects of changes in PA on chronic disease are likely to vary between conditions and depend on personal characteristics, as well as on their magnitude/persistence, population-level monitoring studies should deal with these aspects.

In addition, the impact of an intervention like LLGA is likely to vary not only between individuals and over time, but also on whose economic perspective is taken. In this and previous studies[11,14], costs and benefits (QALYs) falling on the health care sector only were considered. However, results are likely to change when a local public health agency viewpoint is taken. As the body administering and hosting the intervention, the opportunity cost by the Local Authority may not coincide with the budget expenditure. Potential spill-overs from increased numbers of paying members or reductions in member retention due to the intervention might have occurred.

Implications for future research

The results presented here contribute new economic information regarding the value for money of universal programmes to reduce physical inactivity in the general population. A number of limitations have been noted with the analysis reported here, many of which relate to the paucity of data to inform such analysis and a lack of consensus on methodological approaches. Future work should focus on better data collection and assessing the value for money of this type of population-level programmes to inform decisions that often are made outside the health care sector.

Declarations

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

No data are available. Programme data have been provided by the local City Council under a Data
Processing Agreement.

Competing interests

There are no competing interests for any author.

Authors contributions

PC was responsible for designing the study, data analysis, development of the economic model and
drafting the manuscript. DM, AJH and LB contributed to the writing of the manuscript. All authors read
and approved the final version of the manuscript.

Acknowledgments

None.

References

1.   National Institute for Health and Care Excellence. Methods for the development of

NICE public health guidance (third edition) 2012 [Available from:

https://www.nice.org.uk/process/pmg4/resources/methods-for-the-development-of-

nice-public-health-guidance-third-edition-pdf-2007967445701.

2. Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-

communicable diseases worldwide: an analysis of burden of disease and life

expectancy. Lancet 2012;380(9838):219-29. doi: 10.1016/S0140-6736(12)61031-9

3. Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical

inactivity: a global analysis of major non-communicable diseases. Lancet

2016;388(10051):1311-24. doi: 10.1016/S0140-6736(16)30383-X [published Online

First: 2016/08/01]

4. Scarborough P, Bhatnagar P, Wickramasinghe KK, et al. The economic burden of ill

health due to diet, physical inactivity, smoking, alcohol and obesity in the UK: an

update to 2006-07 NHS costs. Journal of Public Health 2011;33(4):527-35. doi:

10.1093/pubmed/fdr033

5. National Institute for Health and Care Excellence. Guide to the methods of

technology appraisal 2013 2013 [Available from:

https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#exploring-

uncertainty.

6. Wu S, Cohen D, Shi Y, et al. Economic analysis of physical activity interventions.

American Journal of Preventive Medicine 2011;40(2):149-58. doi:

http://dx.doi.org/10.1016/j.amepre.2010.10.029

7. Laine J, Kuvaja-Kollner V, Pietila E, et al. Cost-effectiveness of population-level

physical activity interventions: a systematic review. Am J Health Promot

2014;29(2):71-80. doi: 10.4278/ajhp.131210-LIT-622 [published Online First:

2014/11/02]

8.   Lee PH, Macfarlane DJ, Lam TH, et al. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act 2011;8:115. doi: 10.1186/1479-5868-8-115 [published Online First: 2011/10/25]

9.   World Health Organization. What is Moderate-intensity and Vigorous-intensity Physical Activity? 2019 [Global Strategy on Diet, Physical Activity and Health: [Available from: https://www.who.int/dietphysicalactivity/physical_activity_intensity/en/.

10.   Department of Health. Physical activity guidelines for Adults (19–64 years) 2011 [Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d

11.   Frew EJ, Bhatti M, Win K, et al. Cost-effectiveness of a community-based physical activity programme for adults (Be Active) in the UK: an economic analysis within a natural experiment. Br J Sports Med 2014;48(3):207-12. doi: 10.1136/bjsports-2012-091202 [published Online First: 2012/07/17]

12.   Department of Health. NHS Costing Manual 2012 [28]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d

13.   Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015;19(14):1-503, v-vi. doi: 10.3310/hta19140 [published Online First: 2015/02/19]

14.   Gulliford M, Charlton J, Bhattarai N, et al. Social and material deprivation and the cost-effectiveness of an intervention to promote physical activity: cohort study and Markov model. Journal of Public Health 2014;36(4):674-83. doi: 10.1093/pubmed/fdt132

15.   Roux L, Pratt M, Tengs TO, et al. Cost effectiveness of community-based physical

activity interventions. Am J Prev Med 2008;35(6):578-88. doi: 10.1016/j.amepre.2008.06.040 [published Online First: 2008/11/13]

16. Office of Disease Prevention and Health Promotion. Physical Activity Guidelines Advisory Committee Scientific Report 2018 [Available from: https://health.gov/paguidelines/second-edition/report/pdf/04_C_Background_and_Key_Physical_Activity_Concepts.pdf.

17. Maheswaran H, Petrou S, Rees K, et al. Estimating EQ-5D utility values for major health behavioural risk factors in England. J Epidemiol Community Health 2013;67(2):172-80. doi: 10.1136/jech-2012-201019 [published Online First: 2012/07/31]

18. Briggs A, Sculpher, M., Claxton, K.,. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press 2006.

19. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Econ 2004;13(5):405-15. doi: 10.1002/hec.903 [published Online First: 2004/05/06]

20. Sjogaard G, Christensen JR, Justesen JB, et al. Exercise is more than medicine: The working age population's well-being and productivity. Journal of Sport and Health Science 2016;5(2):159-65. doi: 10.1016/j.jshs.2016.04.004

21. Roux L, Pratt M, Lee IM, et al. Does age modify the cost-effectiveness of community-based physical activity interventions? J Phys Act Health 2015;12(2):224-31. doi: 10.1123/jpah.2013-0167 [published Online First: 2014/05/20]

22. Tucker P, Gilliland J. The effect of season and weather on physical activity: a systematic review. Public Health 2007;121(12):909-22. doi: 10.1016/j.puhe.2007.04.009 [published Online First: 2007/10/09]

23. Van Dyck D, Mertens L, Cardon G, et al. Opinions Toward Physical Activity, Sedentary

Behavior, and Interventions to Stimulate Active Living During Early Retirement: A Qualitative Study in Recently Retired Adults. J Aging Phys Act 2017;25(2):277-86. doi: 10.1123/japa.2015-0295 [published Online First: 2016/10/21]

24. Joseph J, Svartberg J, Njolstad I, et al. Incidence of and risk factors for type-2 diabetes in a general population: The Tromso Study. Scandinavian Journal of Public Health 2010;38(7):768-75. doi: 10.1177/1403494810380299

25. Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011;124(7):789-95. doi: 10.1161/CIRCULATIONAHA.110.010710 [published Online First: 2011/08/04]

26. National Institute for Health and Care Excellence. Resource impact statement: Depression and anxiety disorder, 2015.

27. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol a-Biol 2001;56(3):M146-M56. doi: DOI 10.1093/gerona/56.3.M146

28. Meng XF, D'Arcy C. The projected effect of increasing physical activity on reducing the prevalence of common mental disorders among Canadian men and women: A national population-based community study. Prev Med 2013;56(1):59-63. doi: 10.1016/j.ypmed.2012.11.014

29. McPhee JS, French DP, Jackson D, et al. Physical activity in older age: perspectives for healthy ageing and frailty. Biogerontology 2016;17(3):567-80. doi: 10.1007/s10522-016-9641-0

30. Sharma M, Nazareth I, Petersent I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. Bmj Open 2016;6(1) doi: ARTN e010210 10.1136/bmjopen-2015-010210

31. Bajekal M, Scholes S, Love H, et al. Analysing Recent Socioeconomic Trends in

Coronary Heart Disease Mortality in England, 2000-2007: A Population Modelling Study. Plos Medicine 2012;9(6) doi: ARTN e1001237 10.1371/journal.pmed.1001237

32. Bray BD, Paley L, Hoffman A, et al. Socioeconomic disparities in first stroke incidence, quality of care, and survival: a nationwide registry-based cohort study of 44 million adults in England. Lancet Public Health 2018;3(4):E185-E93. doi: 10.1016/S2468-2667(18)30030-6

33. Cancer Research UK. Deprivation gradient for cancer incidence 2011 [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/deprivation-gradient#heading-One.

34. Walters K, Rait G, Griffin M, et al. Recent Trends in the Incidence of Anxiety Diagnoses and Symptoms in Primary Care. Plos One 2012;7(8) doi: ARTN e41670 10.1371/journal.pone.0041670

35. Curtis EM, van der Velde R, Moon RJ, et al. Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status. Bone 2016;87:19-26. doi: 10.1016/j.bone.2016.03.006

36. Nwaneri C, Bowen-Jones D, Cooper H, et al. Falling mortality rates in Type 2 diabetes mellitus in the Wirral Peninsula: a longitudinal and retrospective cohort population-based study. Postgraduate Medical Journal 2012;88(1046):679-83. doi: 10.1136/postgradmedj-2012-130877

37. Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, et al. Prediction of Cardiovascular Events and All-Cause Mortality With Brachial-Ankle Elasticity Index A Systematic Review and Meta-Analysis. Hypertension 2012;60(2):556-+. doi: 10.1161/Hypertensionaha.112.194779

38. Cancer Australia. Bowel cancer statistics 2016 [Available from: https://bowel-cancer.canceraustralia.gov.au/statistics.

39.   Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark. Jnci-J Natl Cancer I 2011;103(18):1363-72. doi: 10.1093/jnci/djr299

40.   Cuijpers P, Vogelzangs N, Twisk J, et al. Comprehensive Meta-Analysis of Excess Mortality in Depression in the General Community Versus Patients With Specific Illnesses. Am J Psychiat 2014;171(4):453-62. doi: 10.1176/appi.ajp.2013.13030325

41.   Kulmala J, Nykanen I, Hartikainen S. Frailty as a predictor of all-cause mortality in older men and women. Geriatr Gerontol Int 2014;14(4):899-905. doi: 10.1111/ggi.12190

42.   Sullivan PW, Ghushchyan VH. EQ-5D Scores for Diabetes-Related Comorbidities. Value in Health 2016;19(8):1002-08. doi: 10.1016/j.jval.2016.05.018

43.   Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Medical Care 2005;43(7):736-49. doi: DOI 10.1097/01.mlr.0000172050.67085.4f

44.   Lin CC, Li CI, Chang CK, et al. Reduced Health-Related Quality of Life in Elders with Frailty: A Cross-Sectional Study of Community-Dwelling Elders in Taiwan. Plos One 2011;6(7) doi: ARTN e21841 10.1371/journal.pone.0021841

45.   Thomas CM, Morris S. Cost of depression among adults in England in 2000. Brit J Psychiat 2003;183:514-19. doi: DOI 10.1192/bjp.183.6.514

46.   46. McNamee P, Gregson BA, Buck D, et al. Costs of formal care for frail older people in England: the resource implications study of the MRC cognitive function and ageing study (RIS MRC CFAS). Social Science & Medicine 1999;48(3):331-41. doi: Doi 10.1016/S0277-9536(98)00351-7

Figures

Figure 1

Schematic of the Markov model

Figure 2

Cost-effectiveness plane

Figure 3

Cost-effectiveness acceptability curve

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

 Appendix I.docx